DRL launches anti-cancer drug in US market - News Summed Up

DRL launches anti-cancer drug in US market


Dr. Reddy s Laboratories Ltd today announced today that it has launched Clofarabine Injection, a therapeutic equivalent generic version of Clolar (clofarabine) Injection in the United States market, following the approval from the US Food and Drug Administration (USFDA). According to a statement issued by the city-based drug maker, its generic version of the injection is available in single-dose, 20 ml flint vials containing 20 mg of clofarabine in 20 ml of solution (1mg/mL). Clolar is a registered trademark of Genzyme Corporation, it said. Clofarabine Injection is used to treat acute Lymphoblastic Leukemia, a cancer of white blood cells. Dr Reddy's shares are trading at Rs 2338.80 apiece on BSE at 1430 hrs.


Source: Economic Times November 14, 2017 09:22 UTC


Loading...
Loading...